Cancer Biomarkers Market By Type (Breast cancer, Liver cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Lung cancer, and Others), By Biomolecule (Genetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, and Others), By Application (Drug discovery & Development, Diagnostics, Personalized medicine, and Others), By Technology (Imaging Technology and OMICS), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Cancer Biomarkers Market size is expected to be worth around US$ 98.1 billion by 2033 from US$ 30.2 billion in 2023, growing at a CAGR of 12.5% during the forecast period 2024 to 2033.

Rising cancer incidence and advancements in precision medicine are driving the growth of the cancer biomarkers market, as these biomarkers play a critical role in early diagnosis, prognosis, and targeted therapy. Cancer biomarkers, which can be genetic, protein, or metabolic markers, are increasingly used to tailor treatments and monitor disease progression in cancers such as breast, lung, and prostate.

In 2022, approximately 20 million people were diagnosed with cancer, and while 53.5 million survived for at least five years, nearly 10 million succumbed to the disease. The World Health Organization identified a significant gap in access to cancer care, with fewer than 40% of countries providing essential cancer treatments and palliative services.

Opportunities in the market include expanding the use of liquid biopsy technologies and the development of novel biomarkers for personalized treatment plans. Recent trends, such as the integration of artificial intelligence in biomarker discovery and real-time monitoring, are transforming cancer care, offering more precise and effective therapies for patients globally.

Key Takeaways

• In 2023, the market for cancer biomarkers generated a revenue of US$ 30.2 billion, with a CAGR of 12.5%, and is expected to reach US$ 98.1 billion by the year 2033.
• The type segment is divided into breast cancer, liver cancer, colorectal cancer, prostate cancer, cervical cancer, lung cancer, and others, with breast cancer taking the lead in 2023 with a market share of 28.7%.
• Considering biomolecule, the market is divided into genetic biomarkers, metabolic biomarkers, proteomic biomarkers, epigenetic biomarkers, and others. Among these, genetic biomarkers held a significant share of 32.6%.
• Furthermore, concerning the application segment, the market is segregated into drug discovery & development, diagnostics, personalized medicine, and others. The diagnostics sector stands out as the dominant player, holding the largest revenue share of 41.9% in the cancer biomarkers market.
• The technology segment is segregated into imaging technology and OMICS, with the imaging technology segment leading the market, holding a revenue share of 63.5%.
• North America led the market by securing a market share of 41.1% in 2023.

Type Analysis

The breast cancer segment led in 2023, claiming a market share of 28.7% owing to the rising prevalence of breast cancer globally and the increasing demand for early detection methods. Biomarkers such as BRCA1 and BRCA2, along with advancements in liquid biopsy technologies, are expected to enhance early diagnosis and treatment monitoring.

The growing awareness of breast cancer screening programs, coupled with advancements in personalized treatment approaches, is projected to further support growth in this segment. Additionally, increasing research investments in identifying novel biomarkers specific to breast cancer are likely to accelerate the adoption of biomarker-based diagnostics and treatments.

Biomolecule Analysis

The genetic biomarkers held a significant share of 32.6% due to the increasing focus on precision medicine and the identification of genetic mutations that drive cancer development. Advances in next-generation sequencing technologies are anticipated to enhance the discovery and validation of genetic biomarkers, which are crucial for targeted therapies.

The rising prevalence of genetic testing for cancer predisposition, particularly in high-risk populations, is likely to drive demand. Additionally, ongoing research into identifying actionable genetic mutations is projected to contribute to the growth of the genetic biomarkers segment, especially in cancers like breast and colorectal cancer.

Application Analysis

The diagnostics segment had a tremendous growth rate, with a revenue share of 41.9% owing to the increasing demand for early and accurate cancer detection methods. Biomarker-based diagnostic tools are expected to enhance the accuracy of cancer screening and diagnosis, allowing for timely treatment interventions.

The growing adoption of non-invasive diagnostic methods, such as liquid biopsy and imaging-based biomarker detection, is likely to support this trend. Additionally, the rise in routine cancer screening programs and the integration of biomarkers into diagnostic assays are projected to further boost the demand for biomarker-based diagnostics, particularly for common cancers like breast and lung cancer.

Technology Analysis

The imaging technology segment grew at a substantial rate, generating a revenue portion of 63.5% due to the increasing use of imaging techniques for the detection, diagnosis, and monitoring of cancer progression. Technologies such as PET, CT, and MRI scans, enhanced by biomarker-driven contrast agents, are expected to improve the accuracy of cancer imaging.

The demand for real-time, non-invasive imaging solutions for detecting tumor markers and monitoring treatment responses is projected to further support growth in this segment. Additionally, the growing use of advanced imaging techniques in clinical trials for cancer drug development is likely to contribute to the expansion of the imaging technology segment.

Key Market Segments

By Type

• Breast cancer
• Liver cancer
• Colorectal cancer
• Prostate cancer
• Cervical cancer
• Lung cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Epigenetic Biomarkers
• Others

By Application

• Drug discovery & Development
• Diagnostics
• Personalized medicine
• Others

By Technology

• Imaging Technology
• OMICS

Drivers

Growing Prevalence Of Breast And Pancreatic Cancer

Rising prevalence of breast and pancreatic cancer is expected to drive the growth of the cancer biomarkers market. Breast cancer remains the most common cancer among women, with 670,000 deaths globally in 2022. Notably, half of these cases occurred in women without specific risk factors beyond sex and age, highlighting the importance of early detection methods like biomarkers.

Pancreatic cancer, another major concern, had an incidence rate of 13.5 per 100,000 men and women annually and a death rate of 11.2 per 100,000. By 2021, approximately 100,669 people were living with pancreatic cancer in the U.S., a disease often diagnosed at advanced stages. The growing burden of these cancers creates a pressing need for effective biomarkers that can detect malignancies early, facilitating timely treatment and improving patient outcomes.

Restraints

Increasing Technical Issues With Sample Collection

Increasing technical issues with sample collection are anticipated to impede the growth of the cancer biomarkers market. Reliable biomarker analysis requires precise and consistent sample collection, but problems such as sample degradation, contamination, or improper handling frequently arise. These technical issues compromise the accuracy and reliability of test results, leading to false positives or negatives, which hampers clinical decision-making.

Inconsistencies in pre-analytical conditions, including storage and transport of samples, further complicate the situation, as different biomarkers may require specific handling procedures. These challenges increase the cost of biomarker research and limit the scalability of biomarker-based diagnostics. As a result, technical difficulties in sample collection continue to restrain the broader adoption of biomarker testing in routine clinical practice.

Opportunities

Rising R&D Activities

Rising research and development (R&D) activities present a significant opportunity for the cancer biomarkers market. Continuous innovation in biomarker discovery and validation offers new avenues for early cancer detection and personalized treatment strategies. In May 2024, Lantern Pharma partnered with Oregon to utilize its RADR AI platform to streamline the development of XCE853, demonstrating how AI is revolutionizing biomarker discovery.

In another major development, Denovo Biopharma received USD 11.8 million from the California Institute for Regenerative Medicine (CIRM) in April 2024 to advance DB107, a gene therapy guided by DGM7 biomarkers for glioblastoma. These R&D initiatives are expected to accelerate the discovery of new cancer biomarkers and therapeutic targets, driving market growth. As more funding and partnerships focus on advanced biomarker research, opportunities for breakthroughs in cancer diagnosis and treatment continue to expand.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic conditions and geopolitical factors heavily influence the cancer biomarkers market. Rising inflation and healthcare costs increase the overall expense of research, diagnostics, and treatment development, limiting access to advanced testing in regions with strained healthcare systems. Economic slowdowns reduce funding for research and innovation, while geopolitical instability and trade restrictions disrupt the supply chain for critical components and technologies.

However, increased government investments in healthcare and rising global awareness of early cancer detection are driving demand for biomarker-based diagnostics. International collaborations and favorable regulatory policies further support the market’s expansion. As healthcare systems across the globe prioritize early cancer detection and personalized medicine, the cancer biomarkers market is expected to see sustained growth despite economic and political challenges.

Trends

Rising Partnerships and Collaborations

Rising partnerships and collaborations are anticipated to drive significant growth in the cancer biomarkers market. In February 2024, C-Biomex Ltd. and the University of Texas MD Anderson Cancer Center announced a strategic partnership to co-develop CBT-001, a radioligand targeting the CA9 biomarker, combining MD Anderson’s radiopharmaceutical expertise with C-Biomex’s innovation.

Similarly, in July 2024, Genoks GDHM and Velsera partnered to enhance cancer diagnostics in Turkey by integrating Velsera’s Clinical Genomics Workspace with Genoks’s genomic capabilities. These collaborations highlight the growing trend of companies and research institutions working together to advance cancer diagnostics and treatment. Increasing cross-border partnerships are projected to accelerate innovation and improve cancer detection methods, driving the market toward new technological breakthroughs and expanded patient access.

Regional Analysis

North America is leading the Cancer Biomarkers Market

North America dominated the market with the highest revenue share of 41.1% owing to increasing demand for early cancer detection and advancements in precision medicine. The region saw significant progress with the approval of new biomarker tests that enhance diagnostic accuracy and patient outcomes. In August 2024, Illumina received USFDA approval for its cancer biomarker test, further solidifying its position in the market.

Additionally, in June 2024, Cizzle Biotechnology Holdings plc announced a collaboration with Cizzle Bio Inc. in the U.S. to include their proprietary CIZ1B biomarker test in a major cancer study at a leading U.S. cancer center. These developments, along with increasing research and government funding for cancer diagnostics, have contributed to the accelerated adoption of biomarker-based tests in North America, driving market expansion.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to increasing cancer incidence and rising healthcare investments in diagnostics. In August 2023, Quest Diagnostics partnered with Envision Sciences to launch a new prostate cancer biomarker test, which targets aggressive forms of the disease. This test, incorporating biomarkers Appl1, Sortilin, and Syndecan-1, was initially researched by the University of South Australia and later developed for commercial use.

The growing focus on early detection and personalized treatment, combined with the expanding healthcare infrastructure in countries such as China, Japan, and India, is anticipated to propel the adoption of innovative biomarker tests. Government initiatives aimed at advancing cancer research and improving patient outcomes are also likely to contribute to market growth across the region.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The major players in the cancer biomarkers market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the cancer biomarkers market focus on developing advanced diagnostic tools that enable early detection and personalized treatment plans.

They invest in research and development to identify novel biomarkers and improve the accuracy of existing tests. Collaborating with pharmaceutical companies and research institutions accelerates the development of targeted therapies. Expanding into emerging markets helps them reach a broader patient population and drive revenue growth. Additionally, they emphasize obtaining regulatory approvals and increasing awareness among healthcare professionals to promote the adoption of their products.

Top Key Players in the Cancer Biomarkers Market

• Siemens Healthineers
• Seegene Technologies Inc.
• Roche
• Meso Scale Diagnostics LLC
• LES LABORATOIRES SERVIER
• Koninklijke Philips N.V.
• Exact Sciences
• Bio-Rad Laboratories Inc.
• Abbott Laboratories

Recent Developments

• In October 2023: Koninklijke Philips N.V. partnered with Quibim to integrate artificial intelligence (AI) into MR imaging and image analysis software, facilitating quicker and more efficient prostate cancer diagnosis and treatment. This collaboration is highly relevant to the growth of the cancer biomarkers market, as it enhances diagnostic accuracy and reduces healthcare delivery costs, addressing key challenges such as staffing shortages and operational efficiency in cancer care.
• In March 2023: LES LABORATOIRES SERVIER partnered with QIAGEN to develop a novel mIDH1 companion diagnostic test for advancing their Hemato-Oncology portfolio. This collaboration focuses on identifying acute myeloid leukemia patients, playing a crucial role in the growth of the cancer biomarkers market by providing precise diagnostic tools that support personalized treatment strategies for blood cancers.
• In April 2021: Roche launched the Elecsys Anti-p53 immunoassay for diagnosing various cancers in CE mark-accepting markets. This immunoassay measures anti-p53 antibodies in serum and plasma, aiding physicians in diagnosing cancers such as throat, bowel, and breast cancers when used alongside other diagnostics. The introduction of this test contributes to the cancer biomarkers market by expanding the range of available diagnostic tools for multiple cancer types, thereby improving early detection and treatment outcomes.

Report Scope